{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:40:04Z","timestamp":1749948004019,"version":"3.41.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","funder":[{"name":"Guangdong Emergency Program for Prevention and Control of COVID-19","award":["2020A1111340002"],"award-info":[{"award-number":["2020A1111340002"]}]},{"name":"Shenzhen Key Research Project for Prevention and Control of COVID-19"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>It is important to extend the indication of severe acute respiratory syndrome coronavirus 2 vaccine to children to improve the vaccine intake rate and reduce infection in this population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In 2 phase 1 and phase 2 randomized, double-blind and placebo-controlled trials, 84 and 480 Chinese healthy children 3 to 17 years old were enrolled, respectively, and randomized in 3:1 ratio to receive 2 doses of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine, KCONVAC or placebo. The 2 doses were given 28 days apart. Adverse events (AEs) were recorded through Day 28 after each dosing. Live virus neutralizing antibody and receptor binding domain antibody (RBD-IgG) were tested before vaccination and after the second dose.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Two doses of the vaccine, KCONVAC, elicited geometric mean titers of 142\u2013150 for neutralizing antibody and 4154\u20134253 for RBD-IgG 28 days after the second dose. Seroconversion rates were 100% after 2 doses for both antibodies in both trials. The predominant AEs were injection-site pain, cough and fever. Most AEs were grade 1 or 2 in intensity. Five participants reported 6 vaccination-unrelated serious AEs in the phase 2 trial.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Two doses of this study vaccine, KCONVAC, were well tolerated and immunogenic in children 3 to 17 years of age.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004085","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T20:03:49Z","timestamp":1693944229000},"page":"1136-1142","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine KCONVAC in Chinese Children: Randomized, Double-blind, Placebo-controlled Phase 1 and 2 Trials"],"prefix":"10.1097","volume":"42","author":[{"given":"Jiankai","family":"Liu","sequence":"first","affiliation":[{"name":"Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoying","family":"Huang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guifan","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Minhai Biotechnology Co., Ltd., Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Huang","sequence":"additional","affiliation":[{"name":"Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danni","family":"Wang","sequence":"additional","affiliation":[{"name":"Xiangtan County for Disease Control and Prevention, Xiangtan, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Institutes for Food and Drug Control, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Deng","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianyun","family":"Chang","sequence":"additional","affiliation":[{"name":"Beijing Minhai Biotechnology Co., Ltd., Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafei","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Minhai Biotechnology Co., Ltd., Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqi","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Minhai Biotechnology Co., Ltd., Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijin","family":"Huang","sequence":"additional","affiliation":[{"name":"National Institutes for Food and Drug Control, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WenJie","family":"Tan","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidong","family":"Gao","sequence":"additional","affiliation":[{"name":"Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019.","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S0140-6736(22)00011-3","article-title":"Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.","volume":"399","author":"Rearte","year":"2022","journal-title":"Lancet"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"e0246326","DOI":"10.1371\/journal.pone.0246326","article-title":"The differential impact of pediatric COVID-19 between high-income countries and low- and middle-income countries: a systematic review of fatality and ICU admission in children worldwide.","volume":"16","author":"Kitano","year":"2021","journal-title":"PLoS One"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/CM9.0000000000001573","article-title":"Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind and placebo-controlled phase 1 and phase 2 clinical trials.","volume":"134","author":"Pan","year":"2021","journal-title":"Chinese Med J"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1093\/infdis\/jiab627","article-title":"Immunogenicity and safety of a three-dose regimen of a SARS-CoV-2 inactivated vaccine in adults: a randomized, double-blind, placebo-controlled phase 2 trial.","volume":"225","author":"Liu","year":"2022","journal-title":"J Infect Dis"},{"key":"R10-20250614","first-page":"51","article-title":"Multi-system inflammatory syndrome in children & adolescents (MIS-C): a systematic review of clinical features and presentation.","volume":"38","author":"Radia","year":"2021","journal-title":"Paediatr Respir Rev"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1007\/s00431-021-03993-5","article-title":"Multisystem inflammatory syndrome in children related to COVID-19: a systematic review.","volume":"180","author":"Hoste","year":"2021","journal-title":"Eur J Pediatr"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1001\/jama.2021.2091","article-title":"Characteristics and outcomes of us children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19.","volume":"325","author":"Feldstein","year":"2021","journal-title":"JAMA"},{"key":"R13-20250614","first-page":"70","article-title":"Challenges of COVID-19 in children in low-and middle-income countries.","volume":"35","author":"Zar","year":"2020","journal-title":"Paediatr Respir Rev"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/s41390-022-02254-x","article-title":"SARS-CoV-2 infection in children and implications for vaccination.","volume":"93","author":"Nathanielsz","year":"2022","journal-title":"Pediatr Res"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S1473-3099(21)00319-4","article-title":"Safety, tolerability and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1\/2 clinical trial.","volume":"21","author":"Han","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1473-3099(21)00462-X","article-title":"Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1\/2 trial.","volume":"22","author":"Xia","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"R18-20250614","first-page":"1","article-title":"Safety and immunogenicity of an inactivated COVID-19 vaccine, WIBP-CorV, in healthy children: interim analysis of a randomized, double-blind, controlled, phase 1\/2 trial.","volume":"13","author":"Xia","year":"2022","journal-title":"Front Immunol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:09:55Z","timestamp":1749946195000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004085","relation":{},"ISSN":["0891-3668"],"issn-type":[{"type":"print","value":"0891-3668"}],"subject":[],"published":{"date-parts":[[2023,9,4]]}}}